Show simple item record

dc.contributor.authorMustafic, Mesud
dc.contributor.authorJandér, Rebecka
dc.contributor.authorMarlevi, David
dc.contributor.authorRickenlund, Anette
dc.contributor.authorRück, Andreas
dc.contributor.authorSaleh, Nawzad
dc.contributor.authorAbdi, Sam
dc.contributor.authorEriksson, Maria J.
dc.contributor.authorDamlin, Anna
dc.date.accessioned2024-06-07T14:08:54Z
dc.date.available2024-06-07T14:08:54Z
dc.date.issued2024-05-28
dc.identifier.issn1868-4300
dc.identifier.issn1868-4297
dc.identifier.urihttps://hdl.handle.net/1721.1/155212
dc.description.abstractThis retrospective cohort study aimed to assess whether basal septal wall thickness (BSWT), anterior (AML) and posterior (PML) mitral leaflet length, or sex were associated with remaining left ventricular outflow tract obstruction (LVOTO) in patients with hypertrophic obstructive cardiomyopathy (HOCM) undergoing alcohol septal ablation (ASA). One hundred fifty-four patients who underwent ASA at the Karolinska University Hospital in Stockholm, Sweden, between 2009 and 2021, were included retrospectively. Anatomical and hemodynamic parameters were collected from invasive catheterization before and during ASA, and from echocardiography (ECHO) examinations before, during, and at 1-year follow-up after ASA. Linear and logistic regression models were used to assess the association between sex, BSWT, AML, PML, and outcome, which was defined as the remaining LVOTO (≥ 30 mmHg) after ASA. The median follow-up was 364 days (interquartile range 334–385 days). BSWT ≥ 23 mm (n = 13, 12%) was associated with remaining LVOTO at follow-up (p = 0.004). Elongated mitral valve leaflet length (either AML or PML) was present in 125 (90%) patients. Elongated AML (> 24 mm) was present in 67 (44%) patients, although AML length was not associated with remaining LVOTO at follow-up. Elongated PML (> 14 mm) was present in 114 (74%) patients and was not associated with remaining LVOTO at follow-up. No significant sex differences were observed regarding the remaining LVOTO. ECHO measurement of BSWT can be effectively used to select patients for successful ASA and identify those patients with a risk of incomplete resolution of LVOTO after ASA.en_US
dc.publisherSpringer Science and Business Media LLCen_US
dc.relation.isversionof10.1007/s12928-024-01014-4en_US
dc.rightsCreative Commons Attributionen_US
dc.rights.urihttps://creativecommons.org/licenses/by/4.0/en_US
dc.sourceSpringer Nature Singaporeen_US
dc.titleAlcohol septal ablation for hypertrophic obstructive cardiomyopathy: do mitral valve leaflet length, septal thickness, or sex affect the outcome?en_US
dc.typeArticleen_US
dc.identifier.citationMustafic, M., Jandér, R., Marlevi, D. et al. Alcohol septal ablation for hypertrophic obstructive cardiomyopathy: do mitral valve leaflet length, septal thickness, or sex affect the outcome?. Cardiovasc Interv and Ther (2024).en_US
dc.contributor.departmentMassachusetts Institute of Technology. Institute for Medical Engineering & Science
dc.identifier.mitlicensePUBLISHER_CC
dc.eprint.versionFinal published versionen_US
dc.type.urihttp://purl.org/eprint/type/JournalArticleen_US
eprint.statushttp://purl.org/eprint/status/PeerRevieweden_US
dc.date.updated2024-06-02T03:14:14Z
dc.language.rfc3066en
dc.rights.holderThe Author(s)
dspace.embargo.termsN
dspace.date.submission2024-06-02T03:14:14Z
mit.licensePUBLISHER_CC
mit.metadata.statusAuthority Work and Publication Information Neededen_US


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record